Evidence map›Paper›PMID 41535474›Full record

ArticleNature2026

The ubiquitin ligase KLHL6 drives resistance to CD8

Hongcheng Cheng, Yapeng Su, Xiaoli Pan, Yue Xu, Ermei Xie, Jing Du, Daniel G Chen, Xiaomeng Dai, Raphael Gottardo, Philip D Greenberg and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Mitochondrial dynamics and T cells immunity in cancer.Biochemistry and biophysics reports · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Post-translational modifications in CD8Frontiers in immunology · 2026
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hongcheng Cheng *National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Suzhou, China.
Yapeng Su *Program in Immunology, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Xiaoli Pan *National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Suzhou, China.
Yue XuNational Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Suzhou, China.
Ermei XieNational Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Suzhou, China.
Jing DuNational Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Suzhou, China.
Daniel G ChenProgram in Immunology, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Xiaomeng DaiNational Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Suzhou, China.
Raphael GottardoHerbold Computational Biology Program, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-3867-0232
Philip D GreenbergProgram in Immunology, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. pgreen@uw.edu.ORCID 0000-0003-3812-647X
Guideng LiNational Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Suzhou, China. lgd@ism.cams.cn.ORCID 0000-0003-0840-7262

Funding

Juno Therapeutics
6 · The paper itself

Abstract

The multifaceted dysfunction of tumour-infiltrating T cells, including exhaustion and mitochondrial dysfunction, remains a major obstacle in cancer immunotherapy

Indexed as

Carrier ProteinsCD8-Positive T-LymphocytesUbiquitin-Protein LigasesAnimalsFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiceMice, Inbred C57BLMitochondriaMitochondrial DynamicsProteasome Endopeptidase ComplexProteolysisReceptors, Antigen, T-CellUbiquitinationCarrier ProteinsKlhl6 protein, mouseProteasome Endopeptidase ComplexReceptors, Antigen, T-CellUbiquitin-Protein Ligases

Identifiers

PMID41535474
PMCPMC12979199

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.